Back to Resource Center

TRIO Study Brief:  Long-Acting Injections for Women’s HIV Prevention in Sub-Saharan Africa: What End-Users Think

TRIO Study Brief: Long-Acting Injections for Women’s HIV Prevention in Sub-Saharan Africa: What End-Users Think

This brief features findings from the Tablets, Ring, Injections as Options (TRIO) study, with a focus on long-acting injections as a delivery form for HIV prevention for women and a potential delivery form for MPTs. 

With injections as a new biomedical HIV prevention strategy on the horizon, the TRIO study’s end-user findings from women and healthcare providers, as outlined in this brief, provide a timely contribution to late-stage product development. Further, they inform market introduction considerations for rollout of injectable delivery forms for women.

TRIO was a multiphase study conducted with young women in Kenya and South Africa between 2015 and 2017 to understand their perspectives on future MPTs. It was led by RTI International with support from the Bill & Melinda Gates Foundation.

View Brief

February 2021

Click for full info +

Full Info:


Resource Type:

Technical Brief

Citation:

This brief features findings from the Tablets, Ring, Injections as Options (TRIO) study, with a focus on long-acting injections as a delivery form for HIV prevention for women and a potential delivery form for MPTs. 

With injections as a new biomedical HIV prevention strategy on the horizon, the TRIO study’s end-user findings from women and healthcare providers, as outlined in this brief, provide a timely contribution to late-stage product development. Further, they inform market introduction considerations for rollout of injectable delivery forms for women.

TRIO was a multiphase study conducted with young women in Kenya and South Africa between 2015 and 2017 to understand their perspectives on future MPTs. It was led by RTI International with support from the Bill & Melinda Gates Foundation. 

Authors:

RTI International | Women’s Global Health Imperative; Impact Research and Development Organization, Kenya; Setshaba Research Centre, South Africa; The Initiative for MPTs (IMPT)

Health Risks(s):

  • HIV
  • Unintended Pregnancy

Product type(s):

  • AVRs
  • Contraceptives
  • Hormonal
  • Injectables
  • MPTs

Topic(s):

  • MPTs
  • Social

    Region(s)

    • Africa

    Back to Resource Center